vs
Side-by-side financial comparison of Gossamer Bio, Inc. (GOSS) and DNA X, Inc. (SONM). Click either name above to swap in a different company.
DNA X, Inc. is the larger business by last-quarter revenue ($16.2M vs $13.8M, roughly 1.2× Gossamer Bio, Inc.). DNA X, Inc. runs the higher net margin — -29.3% vs -342.3%, a 313.0% gap on every dollar of revenue. On growth, Gossamer Bio, Inc. posted the faster year-over-year revenue change (47.1% vs 7.9%).
Gossamer Bio, Inc. is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics for patients with serious immunology, inflammation and oncology conditions. It advances a pipeline of proprietary product candidates across multiple clinical phases, primarily serving healthcare markets in North America and other global regions.
GOSS vs SONM — Head-to-Head
Income Statement — Q4 FY2025 vs Q3 FY2025
| Metric | | |
|---|---|---|
| Revenue | $13.8M | $16.2M |
| Net Profit | $-47.2M | $-4.8M |
| Gross Margin | — | 11.2% |
| Operating Margin | -333.6% | -24.5% |
| Net Margin | -342.3% | -29.3% |
| Revenue YoY | 47.1% | 7.9% |
| Net Profit YoY | -43.0% | -89.2% |
| EPS (diluted) | $-0.21 | $-4.83 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $13.8M | — | ||
| Q3 25 | $13.3M | $16.2M | ||
| Q2 25 | — | $11.2M | ||
| Q1 25 | — | $16.7M | ||
| Q4 24 | — | $15.3M | ||
| Q3 24 | — | $15.0M | ||
| Q2 24 | $95.8M | $11.5M | ||
| Q1 24 | $0 | $9.1M |
| Q4 25 | $-47.2M | — | ||
| Q3 25 | $-48.2M | $-4.8M | ||
| Q2 25 | — | $-7.5M | ||
| Q1 25 | — | $458.0K | ||
| Q4 24 | — | $-21.6M | ||
| Q3 24 | — | $-2.5M | ||
| Q2 24 | $49.2M | $-6.6M | ||
| Q1 24 | $-41.9M | $-2.9M |
| Q4 25 | — | — | ||
| Q3 25 | — | 11.2% | ||
| Q2 25 | — | 7.6% | ||
| Q1 25 | — | 50.0% | ||
| Q4 24 | — | -1.2% | ||
| Q3 24 | — | 28.2% | ||
| Q2 24 | — | 25.8% | ||
| Q1 24 | — | 31.8% |
| Q4 25 | -333.6% | — | ||
| Q3 25 | -369.4% | -24.5% | ||
| Q2 25 | — | -60.2% | ||
| Q1 25 | — | 3.9% | ||
| Q4 24 | — | 55.3% | ||
| Q3 24 | — | -15.8% | ||
| Q2 24 | 54.3% | -56.2% | ||
| Q1 24 | — | -29.5% |
| Q4 25 | -342.3% | — | ||
| Q3 25 | -362.7% | -29.3% | ||
| Q2 25 | — | -66.8% | ||
| Q1 25 | — | 2.7% | ||
| Q4 24 | — | -141.6% | ||
| Q3 24 | — | -16.7% | ||
| Q2 24 | 51.4% | -57.5% | ||
| Q1 24 | — | -31.9% |
| Q4 25 | $-0.21 | — | ||
| Q3 25 | $-0.21 | $-4.83 | ||
| Q2 25 | — | $-0.79 | ||
| Q1 25 | — | $0.08 | ||
| Q4 24 | — | $-116.99 | ||
| Q3 24 | — | $-9.32 | ||
| Q2 24 | $0.22 | $-1.41 | ||
| Q1 24 | $-0.19 | $-0.65 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $136.9M | $2.1M |
| Total DebtLower is stronger | — | $5.1M |
| Stockholders' EquityBook value | $-122.8M | $-701.0K |
| Total Assets | $172.2M | $40.2M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $136.9M | — | ||
| Q3 25 | $180.2M | $2.1M | ||
| Q2 25 | — | $2.0M | ||
| Q1 25 | — | $2.1M | ||
| Q4 24 | — | $5.3M | ||
| Q3 24 | — | $9.1M | ||
| Q2 24 | $354.5M | $9.6M | ||
| Q1 24 | $244.4M | $9.3M |
| Q4 25 | — | — | ||
| Q3 25 | — | $5.1M | ||
| Q2 25 | — | $2.9M | ||
| Q1 25 | — | $2.8M | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $-122.8M | — | ||
| Q3 25 | $-82.3M | $-701.0K | ||
| Q2 25 | — | $-1.3M | ||
| Q1 25 | — | $-1.1M | ||
| Q4 24 | — | $-5.7M | ||
| Q3 24 | — | $15.3M | ||
| Q2 24 | $81.5M | $17.5M | ||
| Q1 24 | $26.7M | $19.8M |
| Q4 25 | $172.2M | — | ||
| Q3 25 | $208.8M | $40.2M | ||
| Q2 25 | — | $36.1M | ||
| Q1 25 | — | $36.0M | ||
| Q4 24 | — | $39.7M | ||
| Q3 24 | — | $49.1M | ||
| Q2 24 | $373.4M | $45.9M | ||
| Q1 24 | $259.4M | $42.4M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-48.3M | $-7.0M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | 0.0% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-48.3M | — | ||
| Q3 25 | $-36.2M | $-7.0M | ||
| Q2 25 | — | $-4.9M | ||
| Q1 25 | — | $-9.6M | ||
| Q4 24 | — | $-4.5M | ||
| Q3 24 | — | $-417.0K | ||
| Q2 24 | $116.3M | $-3.4M | ||
| Q1 24 | $-52.3M | $-168.0K |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $-4.5M | ||
| Q3 24 | — | $-554.0K | ||
| Q2 24 | — | $-3.4M | ||
| Q1 24 | — | $-198.0K |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | -29.6% | ||
| Q3 24 | — | -3.7% | ||
| Q2 24 | — | -29.8% | ||
| Q1 24 | — | -2.2% |
| Q4 25 | 0.0% | — | ||
| Q3 25 | 0.0% | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 0.1% | ||
| Q3 24 | — | 0.9% | ||
| Q2 24 | 0.0% | 0.3% | ||
| Q1 24 | — | 0.3% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | -20.97× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | 2.36× | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
